Human Subjects Core
人类受试者核心
基本信息
- 批准号:10023589
- 负责人:
- 金额:$ 48.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcuteBenignBiologicalBloodCharacteristicsClinicalClinical DataCodeCollectionComplexComputer softwareConsentCoordination and CollaborationDataData AnalysesDatabasesDropsEligibility DeterminationEnrollmentEnsureFloorFreezingFutureHematologistHematologyHemoglobinopathiesHemolysisHuman ResourcesInfrastructureLaboratoriesLogisticsNew YorkPatient CarePatient RecruitmentsPatient SchedulesPatientsPersonsPhysiciansPositioning AttributeQuality ControlResearchResearch ActivityResearch PersonnelResearch Project GrantsSamplingSickle Cell AnemiaSpecialistSpecimenStudy SubjectTimeTransfusionUpdateVideoconferencesWorkbasebiobankcentral databaseclinical applicationclinical developmentclinical materialclinical research siteclinically relevantcloud basedexperiencehuman subjectinsightinterestmeetingsmouse modelprogramssample collectiontransfusion medicine
项目摘要
Summary / Abstract
The Human Subjects Core B, physically located at the New York Blood Center, will have a centralized function
of 1) optimizing collection of high quality biologic specimens and clinical data to support the proposed studies in
the four projects described in this PPG application , and 2) providing clinically-based insights and analysis to the
laboratory-based investigators on their research projects. The Core will be the primary contact with the
institutional co-investigators to maximize the work efficiency. The aims of the Core include to ensure the timely
and proper collection, transport, distribution, storage, and tracking of high-quality research samples through use
of an centralized cloud-based database and weekly meetings with the clinical and lab investigators (Aim1); to
establish and actively maintain the centralized database of high-quality human subject clinical information to
ensure timely and accurate correlation and annotation of clinical variables to laboratory analyses (Aim 2) and to
provide clinical expertise and insight in both benign hematology and transfusion medicine to the laboratory-based
investigators on their research projects and laboratory data interpretation (Aim 3). Provision of such critical
clinical material together with the clinical expertise of the Core will facilitate and enhance the clinical applicability
of the findings emerging from this Program Project.
摘要/摘要
人类受试者核心 B 物理位置位于纽约血液中心,将具有集中功能
1)优化高质量生物标本和临床数据的收集,以支持拟议的研究
本 PPG 申请中描述的四个项目,以及 2) 为患者提供基于临床的见解和分析
实验室研究人员进行他们的研究项目。核心将是与
机构共同研究者,最大限度地提高工作效率。核心目标包括确保及时
通过使用正确收集、运输、分发、储存和跟踪高质量研究样本
基于云的集中数据库以及与临床和实验室研究人员的每周会议(目标1);到
建立并积极维护高质量人类受试者临床信息的集中数据库
确保临床变量与实验室分析的及时、准确的关联和注释(目标 2)并
为实验室提供良性血液学和输血医学方面的临床专业知识和见解
研究人员对其研究项目和实验室数据解释(目标 3)。提供此类关键的
临床材料与核心的临床专业知识一起将促进和增强临床适用性
本计划项目的调查结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Patricia Ann Shi其他文献
Patricia Ann Shi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Patricia Ann Shi', 18)}}的其他基金
TREATMENT POOR HEMATOPOIETIC STEM CELL MOBILIZATION WITH G-CSF & ALBUTEROL
用 G-CSF 治疗造血干细胞动员不良
- 批准号:
7953715 - 财政年份:2009
- 资助金额:
$ 48.17万 - 项目类别:
Phase 1-2 trial of Gamunex (intravenous gammaglobulin) for Sickle Cell Acute Pain
Gamunex(静脉注射丙种球蛋白)治疗镰状细胞性急性疼痛的 1-2 期试验
- 批准号:
7563405 - 财政年份:2008
- 资助金额:
$ 48.17万 - 项目类别:
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin
静脉注射丙种球蛋白治疗镰状细胞性急性疼痛发作
- 批准号:
8547090 - 财政年份:2008
- 资助金额:
$ 48.17万 - 项目类别:
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin
静脉注射丙种球蛋白治疗镰状细胞性急性疼痛发作
- 批准号:
7469764 - 财政年份:2008
- 资助金额:
$ 48.17万 - 项目类别:
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin
静脉注射丙种球蛋白治疗镰状细胞性急性疼痛发作
- 批准号:
8126402 - 财政年份:2008
- 资助金额:
$ 48.17万 - 项目类别:
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin
静脉注射丙种球蛋白治疗镰状细胞性急性疼痛发作
- 批准号:
7685446 - 财政年份:2008
- 资助金额:
$ 48.17万 - 项目类别:
Treatment of sickle cell acute pain episodes with intravenous gammagblobulin
静脉注射丙种球蛋白治疗镰状细胞性急性疼痛发作
- 批准号:
7916430 - 财政年份:2008
- 资助金额:
$ 48.17万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 48.17万 - 项目类别:
Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
- 批准号:
10359959 - 财政年份:2022
- 资助金额:
$ 48.17万 - 项目类别:














{{item.name}}会员




